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Objective. To investigate the eﬀects of bright light treatment for secondary outcome measures and to explore and validate
empirically derived subgroups and treatment eﬀects in subgroups. Methods. A descriptive design. A sample of forty-nine persons
(meanage of 45.8) with clinically assessed seasonalaﬀective disorder (SAD) or subsyndromal SAD (S-SAD) participated in a two-
group clinical trial evaluating the eﬀects of treatment with bright light therapy. A person-oriented cluster analysis was applied
to study treatment eﬀects in subgroups. Results. For the merged group, sleepiness (Epworth Sleepiness Scale), fatigue (fatigue
questionnaire), and health-related quality of life (SF-36) were improved at posttreatment, and results were maintained at the one-
month followup. Three distinct subgroups had a high level of fatigue in common, while the level of excessive daytime sleepiness
and depressed mood diﬀered between the subgroups. Over time, all subgroups improved following ten days treatment in a light
room. Conclusion. Fatigue, excessive daytime sleepiness, and health-related quality of life improve in a similar way as depressed
mood following treatment with bright light. The treatment was eﬀective irrespective of the severity of the disorder, that is, for
persons with SAD and subsyndromal SAD.
1.Introduction
Seasonal variation in mood and behaviour (seasonality) is
common [1, 2] and is associated with self-reports of anxiety
and depression [3]. It has been suggested that a combination
of vulnerability to both seasonality and depression may
b er e l a t e dt os e a s o n a la ﬀective disorder (SAD), a seasonal
subtype of major depression [4, 5]. Diﬀerent combinations
of vulnerability for the two presentations may explain the
variety of symptoms found in SAD and in the milder form
of SAD, subsyndromal SAD (S-SAD) [6]. The recurring sea-
sonal symptoms are triggered by changes in environmental
factors, especially reduced daylight in winter [7]. Replacing
some of the deﬁcient daylight during the winter season
is one way of managing the symptoms. Treatment with
strong artiﬁcial light, bright light therapy (BLT), has shown
promising results in SAD [8, 9] .T h e r ei ss o m ee v i d e n c et h a t
BLT is eﬀective in S-SAD as well [10].
The majority of studies investigating the eﬀects of BLT
have involved the use of light boxes, that is, portable devices
that can be used for treatment in patients’ home environ-
ment. Another form of BLT is provided in light rooms,
originally designed for research purposes at the Karolinska
Institute in Stockholm (Sweden) in order to obtain accurate
measurements of the light dose in diﬀerent experiments
concerned with the hormonal eﬀects of light in humans
[11]. This concept was further evolved into light rooms
for treatment studies in Sweden in the 1980s and 1990s in
order to improve the control of treatment compliance, to
be able to treat a group of patients (and not one individual
a tat i m e )a n dt ob ea b l et of o l l o wt h es y m p t o m so fe a c h
patient on a daily basis (L. Wetterberg, pers. comm. 2009-
01-11). Light rooms for research purposes were developed
in Finland during the same time period [12]. When using
a light box, the light intensity is strongly inﬂuenced by the
distance between the eyes and the light source [13, 14]. In2 Depression Research and Treatment
a light room, the light is indirect and evenly distributed in
the room, and therefore it is possible to obtain more reliable
estimates of the light dose (duration × intensity) compared
to when the light box is used. During treatment, which is
carried out in a similar way as a treatment with the light box
(i.e.,dailytreatmentsinthemorning fortenconsecutivedays
including followup treatments when appropriate), patients
sit comfortably on chairs reading, writing, or talking. There
is no standard for the light intensity in a light room, and
consequently, these vary approximately between 1500 and
6000Lux (clinical experience). Because of the diﬀerences
between these two modes of treatments, results from clinical
studies using light boxes cannot automatically be applied to
light room treatments. These two forms of BLT certainly
have the bright light in common but diﬀer in several other
aspects that may aﬀectoutcome.Forexample, staﬀ andother
patients are present in the light room, while family members
may be present during treatment in home environments.
The majority of light rooms in Swedish health care are
situated in psychiatric clinics, a few in primary health care
or at sleep disorders clinics. An estimate showed that 39
out of 99 responding psychiatric departments provided light
room treatments, which indicate that it is a fairly common
treatment in Sweden [15]. When the Swedish Council on
Technology Assessments in Health Care (the SBU) reviewed
the evidence for BLT in 2004 and 2007, they concluded
that the evidence for BLT in general and treatment in a
light room in particular was not suﬃcient and called for
additional controlled clinical trials [15, 16]. Up to that date,
there were only two publications of clinical trials concerned
with treatment in light rooms, one in 1993 by Partonen et al.
in Finland [12] and the other in 1995 by Thal´ en et al. in
Sweden [17].
More recently, a randomized controlled clinical trial
including a waiting-list control condition showed that BLT
(treatments given in four light rooms) had a positive eﬀect
on depressive mood in persons with SAD and S-SAD and
thatresultswere maintained duringtheone-month followup
[18]. Similar to most clinical studies concerned with the
treatment of SAD and S-SAD, the outcome measure in that
study was depressive mood. However, since the symptoms in
S-SAD may present as tiredness, fatigue, and sleep problems
rather than depressed mood [1], it may be of importance
to assess other variables when evaluating the eﬀects of the
intervention [19]. Therefore, in the above clinical study,
reliable and valid measures of excessive daytime sleepiness,
fatigue, and health-related quality of life (HRQOL) were
used in addition to measures of depressed mood in order
to evaluate treatment eﬀects of bright light in a more
comprehensive way.
Cluster analysis is a multivariate statistics method that
has been used in psychiatric and other research in order
to discover “natural subgroups” and to create empirically
based classiﬁcation of clinical syndromes [20]. Would such
an analysis, performed in the present sample with SAD and
S-SAD and based on a broader range of measures, result
in subgroups that were clinically meaningful and useful?
Results from an early study of seasonality in the population
using cluster analysis and published by Bartko and Kasper
in 1989 identiﬁed eight clusters/subgroups among persons
with seasonal changes in mood and behaviour [21]. The
cluster analysis in that study was based solely on results for
the Seasonal Pattern Assessment Questionnaire (SPAQ) [6],
and two of the clusters were identiﬁed as winter SAD and
S-SAD.
In the present study, the aim was to investigate the use
of more elaborated outcome measures in clinical trials of
BLT, and at the same time to explore and empirically validate
subgroups in that sample with SAD and S-SAD. The study
was performed in several interrelated steps. More speciﬁc
research questions were to (i) study the eﬀects of bright light
therapy on daytime sleepiness, fatigue, and health-related
qualityoflife,(ii)identifyandexploresubgroupswithcluster
analysis basedonmeasures ofdepression,daytimesleepiness,
and fatigue, and (iii) validate these subgroups on cluster
variables, other independent variables, and over time.
2.Method
2.1. Subjects and Procedure. Fifty subjects with SAD or S-
SAD, forty women and ten men (mean age of 45.8, range
of 20–68 years) living in the Swedish county of Dalarna
(lat 60.5), were recruited from a previous population-based
prevalence study [2]. In that study, subjects (N = 312)
scoring above the commonly used cutoﬀsf o rS A Da n d
S-SAD on the Seasonal Pattern Assessment Questionnaire
(SPAQ) [22] were interviewed by telephone (ﬁrst author)
and then clinically assessed by a psychiatrist in a face-
to-face interview (N = 91). Subjects were included if
they fulﬁlled criteria for SAD, that is, a major depressive
disorder with a winter seasonal pattern (DSM-IV) [4]o rS -
SAD according to the commonly used Kasper criteria [22].
Exclusioncriteriawereseverepsychiatricorsomaticdisorder,
prescribed antidepressive medication, an eye condition that
could be negatively aﬀected by bright light, pregnancy, shift
work,previoustreatmentwithBLT,orinadequateknowledge
of the Swedish language.
When subjects experienced relapse of winter depressive
symptoms, baseline data were collected with subsequent
randomisation to either ten days BLT or a 3-week waiting-
listcontrolconditionfollowed byBLT.Alldatawerecollected
the week before treatment, the week after treatment ended,
and at the one-month followup. The study was conducted
during two subsequent winter seasons. Results for the
main outcome variable (depressive mood) and details of
demographic variables, subjects’ progression throughout the
study, the intervention, and attrition are reported elsewhere
[18].
In the present study, baseline data for the total group
(N = 49) were used in the cluster analysis. Complete data
(i.e., baseline, posttreatment, and followup) were available
for 47 out of 49 subjects; one subject declined participation
after baseline, and one subject was lost to posttreatment
data due to a short period of somatic ill health. Written
informed consent was obtained from all participants prior
to their inclusion in the study. The study was approved by
the Research Ethics Committee of the Faculty of Medicine at
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2.2. Measures. The Structured Interview Guide for the
HamiltonDepressionRatingScale-SeasonalAﬀectiveDisorders
self-rating version (SIGH-SAD/SR) [23] is one of the most
commonly used outcome measures in clinical trials of BLT.
It consists of two subscales, the 21-item HAM-D (HAMD-
21) and the 8-item atypical symptom score (Atyp-8). Since
the two subscales measure diﬀerent aspects of SAD, general
depressive symptoms, and symptoms speciﬁc for SAD, the
scores of each subscale were used.
The fatigue questionnaire (FQ) was originally developed
within a primary care setting [24]. Eleven items concern
fatigue experienced during the last month (was changed to
the last week in the present study), and two items concern
the duration of fatigue. The total score varies from 0 to 33,
and it was this score that was used for the analysis. Age- and
gender-speciﬁc norms for the general population have been
published [25].
The Epworth Sleepiness Scale (ESS) is a self-report
questionnaire commonly used in sleep research as a measure
of persistent day-time sleepiness [26]. The eight items cover
activeandpassivesituations inwhich theriskoffalling asleep
or “dozing oﬀ” is estimated on a scale ranging from 0 to 3.
T h es u ms c o r e sr a n g ef r o m0t o2 4 .
The SF-36 is a measure of health-related quality of life
(HRQOL) in the population, but is used as an outcome
measure in treatment studies as well [27]. The thirty-six
items are summed up in 8 subscales; the ﬁrst four subscales
constitutethe physical componentsummary scale (PCS)and
the last four subscales the mental component summary scale
(MCS). The seven-day version of the SF-36 was used in the
presentstudy.NormsforthegeneralSwedish populationand
diﬀerent subgroups are available [27].
Two bivariate visual analogue scales (VASs) measuring
mood (very sad-very happy) and sleepiness (very sleepy-
very alert) were used. Subjects were instructed to put a
mark according to the present situation on a 100mm vertical
line with end-point values only. The VAS scales were ﬁlled
out daily during one week at baseline, posttreatment, and
followup. The mean weekly value for each individual was
used in the analysis.
The Seasonal Pattern Assessment Questionnaire (SPAQ)
was developed during the 1980s as a screening instrument
for seasonal symptoms [6]. The part most commonly used
in the SPAQ is the global seasonal score (GS-score), a
sum score of 6 items concerned with seasonal changes in
energy level, mood, sleep length, social activity, weight, and
appetite. These items are scored from 0 to 4 (no change-
extremely marked change) and the total GS score varies from
0 to 24.
2.3.Relations betweenMeasures. Relationsbetweenmeasures
were analyzed with Pearson correlation coeﬃcients.Ifseveral
outcome measures were to be used in the cluster analysis,
the correlations between them would have to be moderate.
Correlations <0.7 are preferred since they indicate that
measures are related but not identical [28]. Even though the
correlations were within the preferred range, the ESS had a
surprisingly low correlation to the other measures (Pearson r
(range) = 0.0–0.2).
2.4. Statistical Analysis. The few single items missing
(<0.5%) in the SIGH-SAD/SR were imputed using the
method of last value carried forward [29]o rw i t hz e r oi f
missing at baseline. The few missing single items (<0.5%)
in the SF-36 were imputed according to the manual [27].
For VAS, a minimum of 5/7 daily scorings were considered
suﬃcient. There were no single items missing in the VAS,
ESS, or FQ. Treatment eﬀects were analyzed with one-way
repeated measures ANOVAsand subsequentBonferroni post
hoc tests.
Before performing cluster analysis, all scores were trans-
formed into z-scores. The squared Euclidian distance was
used as a similarity measure [30]. Variables used in the
cluster analysis were individual results on the two subscales
HAMD-21 and Atyp-8 (from the SIGH-SAD/SR), the total
s c o r eo nt h ef a t i g u eq u e s t i o n n a i r e( F Q ) ,a n dt h eE p w o r t h
Sleepiness Scale (ESS). Subgroups were identiﬁed with
Ward’s method, which is a hierarchical agglomerative cluster
analysis method that does not require prior knowledge of
the number of clusters. It is suitable for small samples,
and results are presented graphically in a dendrogram [30].
Diﬀerences between clusters at baseline were analyzed with
one-way ANOVAs. Validation of clusters on demographic
variables was performed with Chi-square tests (nominal
data), Fisher’s exact tests (when expected values for the
number of cases/cells were <5), or Kruskal-Wallis test (ordi-
nal data). Demographic variables were dichotomized before
performing the validation analysis. Diﬀerential outcomes
(after BLT) in the clusters were analyzed with group × time
repeated measure ANOVAs (results presented in box plots).
At w o - t a i l e dP value of .05 was used. All analyses were
performed in SPSS, version 15.
3.Results
3.1. Eﬀects of Bright Light Therapy for the Total Group on
Measures of Fatigue, Sleepiness, and Health-Related Quality of
Life. Mean values on the FQ, the ESS, the SF-36, and VAS-
ratings of mood and sleepiness at baseline, posttreatment,
and at the one-month followup are presented in Table 1
(N = 47). Scores on all measures improved, and results were
maintained at the one-month followup.
3.2. Identifying and Exploring Subgroups with Cluster Anal-
ysis. Results from the cluster analysis are presented in
Figure 1. A visual inspection of the dendrogram based on
the size of and relative distance between the clusters resulted
in the choice of a three-cluster solution for further analysis.
Mean values for the clustering variables in each cluster
are presented in Table 2. The clusters were characterized
primarily on the basis of diﬀerential degrees of depression
and sleepiness. Even though fatigue scores also diﬀered
between the clusters, these scores were high compared to
population norms in all three clusters. On the basis of these
similarities and diﬀerences, the conditionwinter SAD and S-
SAD was labelled “winter fatigue,” and the three subgroups
presented according to the level of depression and sleepiness,
that is, “mildly depressed, not sleepy,” “mildly depressed,
sleepy,” and “depressed, sleepy” (Table 2).4 Depression Research and Treatment
Table 1: Mean values (SD) for daytime sleepiness, fatigue, and quality of life in subjects with mild-to-moderate winter depressive mood at
baseline, posttreatment, and at the one-month followup (N = 47). Treatment refers to bright light therapy in a light room.
Measure
Baseline Posttreatment Followup Within-subjects repeated measures ANOVA
Mean (SD) Mean (SD) Mean (SD) F(df)5 P value
Fatigue questionnaire (FQ)1 19.3 (4.2) 10.7 (7.7) 9.5 (9.8) 24.7(1.7,79.4) <.001
Epworth Sleepiness Scale (ESS)2 10.0 (4.1) 6.4 (4.0) 5.5 (3.1) 59.1 (2,90) <.001
VAS3
Mood 49.5 (11.7) 65.5 (15.6) 70.4 (15.1) 57.1 (1.6,75.8) <.001
Sleepiness 36.1 (14.9) 60.8 (20.0) 68.5 (14.2) 82.8 (1.7,77.9) <.001
SF-364
Physical health (PCS) 47.7 (7.4) 49.0 (6.7) 51.1 (6.6) 6.0 (2,92) =.004
Physical functioning (PF) 83.3 (12.9) 87.3 (11.5) 90.2 (10.9) 11.7 (1.8,80.6) <.001
Role—physical (RP) 58.5 (33.1) 78.2 (31.1) 90.4 (19.2) 20.0 (2,92) <.001
Bodily pain (BP) 57.6 (26.8) 71.7 (23.6) 76.6 (23.6) 17.6 (1.8,80.5) <.001
General health (GH) 63.8 (23.1) 70.9 (19.0) 75.4 (17.0) 14.6 (2,92) <.001
Mental health (MCS) 31.8 (10.4) 46.2 (11.0) 49.8 (8.9) 66.7 (2,92) <.001
Vitality (VT) 30.1 (16.8) 61.9 (22.6) 69.1 (17.1) 82.5 (2,92) <.001
Social functioning (SF) 62.8 (23.4) 80.9 (21.8) 91.5 (14.1) 35.8 (2,92) <.001
Role—emotional (RE) 43.3 (41.1) 80.1 (29.2) 88.7 (24.4) 43.5 (1.6,72.3) <.001
Mental health (MH) 56.4 (16.6) 75.1 (18.4) 79.6 (14.5) 38.4 (2,92) <.001
N (%) N (%) N (%)
Proportion with ESS total score ≤86 13 (27.7) 38 (80.0) 39 (84.8)
Proportion with FQ total score ≤127 3 (6.4) 34 (72.3) 39 (83.0)
1High values correspond to high level of fatigue (feeling worse).
2High values correspond to high level of sleepiness(feeling worse).
3Four uni- or Two bivariate 0–100 visual analogue scales. Low values correspond to high level of depressive mood/sleepiness (feeling worse).
4Low values correspond to lower level of functioning (feeling worse).
5When Mauchly’s test of sphericity was signiﬁcant, a Greenhouse-Geisser correction of degrees of freedom was used. P values refer to diﬀerences between
baseline and the one-month followup.
6Scores <8 are considered to be within the normal range [26].
7The score 12 represents approximately the population mean [25].
Table 2: Mean values (SD) for the cluster variables in the three clusters at baseline (N = 49).
Cluster variables
Winter fatigue
Mildly depr/Not Sleepy Mildly depr/Sleepy Depressed/Sleepy Between-groups ANOVA
N = 9 N = 23 n = 17 F(2,48) P value
HAMD-21 (SD) 12.9 (4.1) 11.4 (5.0) 20.4 (6.2) 14.7 <.001
Atyp-8 (SD) 6.9 (2.8) 6.3 (2.7) 12.3 (2.6) 26.3 <.001
FQ (SD) 16.9 (2.1) 17.7 (4.2) 23.4 (1.8) 18.8 <.001
ESS (SD) 3.8 (2.2) 11.7 (3.1) 11.5 (2.6) 28.7 <.001
3.3. Validation of Clusters on Demographic Variables, Other
Measures, and Over Time. There were no statistically sig-
niﬁcant diﬀerences between clusters on the variables age,
sex, civil status, education, duration of seasonal symptoms,
comorbid disorders, or medication. A diﬀerence between
the clusters was found for one variable; that is, present
occupation (working versus being sick listed or retired
(Fischer’s exact test, P = .047). However, this diﬀerence
between the clusters was not considered to have any major
impact on the interpretation of results since the majority in
t h es a m p l ew a si nf a c te m p l o y e d( N = 44/49).
Between-groups ANOVA showed signiﬁcant diﬀerences
between the clusters on the SF-36, VAS, and the SPAQ GS-
score (Table 3). The “depressed-sleepy” cluster had lower
scores than the other two clusters on all scales in the
SF-36. Several of the subscale scores were strikingly low
for the “depressed-sleepy” cluster. All the three clusters
had low scores on the MCS (mental component summary
scale) and the VT (vitality) subscale. The PCS (physical
component summary score) was lower compared to norms
in the “depressed-sleepy” subgroup only. The perception of
general health (GH) and bodily pain (BP) diﬀered betweenDepression Research and Treatment 5
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Figure 1: A hierarchical cluster analysis (Ward’s method) of subjects with winter SAD and S-SAD (N = 49) based on baseline data taken
from four measures: the fatigue questionnaire (FQ), the Epworth Sleepiness Scale (ESS), and the two subscales, the HAMD-21 and Atyp-8
(from the depression scale SIGH-SAD/SR).
the two mildly depressed clusters: the “mildly depressed-not
sleepy” and the “mildly depressed-sleepy” clusters (Table 3).
To summarize, the mental health scales in the SF-36 were
notably low for all clusters, while the physical health scales
were low in the “depressed-sleepy” subgroup only.
Results on the VAS sleepiness scale were consistent with
other measures, that is, were lower in the two subgroups
labeled “sleepy,” that is, the “mildly depressed-sleepy” and
“depressed-sleepy” clusters. Levels of the VAS mood scale
did not diﬀer between the clusters. The SPAQ GS-score was
higher (worse) in the “depressed-sleepy” cluster compared
with the other two clusters.
Whenevaluating diﬀerential outcomeofBLT in the three
clusters, there were signiﬁcant group x time interactions
for the ESS, F(4,86) = 5.3, P ≤ .001 and the 29-item
SIGH-SAD/SR total score, F(3.4,74.3) = 6.2, P<. 001.
T h e r ew e r en os u c hg r o u pxt i m ei n t e r a c t i o n sf o rt h eF Q ,
F(3.5,76.8) = 1.9, n.s., the SF-36 PCS, F(4,88) = 2.3,
n.s., the SF-36 MCS, F(4,88) = 1.5, n.s., the VAS mood
scale, F(3.3,72.4) = 0.3, n.s., or the VAS sleepiness scale,
F(3.4,75.0) = 0.5, n.s. The median values at baseline,
posttreatment, and the one-month followup including some
commonly used cutoﬀs/population means are presented in
Figure 2.6 Depression Research and Treatment
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Figure 2: The box plots (a)–(e) illustrate results from ANOVA repeated measures analysis of the clusters/subgroups at baseline,
posttreatment,andone-monthfollowup.Areference(horizontal)lineisgivenforeachmeasure;thefatiguequestionnaire(FQ),apopulation
meanset at12.2[25] andthe Epworth Sleepiness Scale(ESS),a cutoﬀ forexcessive daytime sleepiness set at ≥10 [26]. Two reference linesare
given for the 29-item SIGH-SAD/SR depression scale, one representing scores for individuals without depressive symptoms set at ≤8[ 31]
andthe other indicatingpossible depressionset at ≥20 [32]. The reference lines for the SF-36 PCS (physical component summaryscale) and
MCS (mental component summary scale) represent mean values for the general population set at 50 [27].Depression Research and Treatment 7
Table 3: Results for the three clusters on independent measures at baseline, that is, other measures than those used in the formation of
clusters at baseline (N = 49).
Measure
Winter fatigue
Mildly depr-Not Sleepy Mildly depr-Sleepy Depressed-Sleepy Between-groups ANOVA
Mean (SD) Mean (SD) Mean (SD) F(2,48) P value
SF-361
Physical health (PCS) 48.8 (4.2) 51.3 (6.3) 40.5 (6.9) 15.2 <.001
Physical functioning (PF) 85.6 (11.8) 87.8 (10.4) 71.8 (15.9) 8.1 ≤.001
Role—physical (RP) 72.2 (19.5) 73.9 (27.7) 23.5 (24.2) 21.8 <.001
Bodily pain (BP) 56.7 (29.6) 67.1 (21.3) 42.2 (26.9) 4.9 ≤.01
General health (GH) 59.0 (20.4) 76.0 (17.2) 47.6 (21.7) 10.6 <.001
Mental health (MCS) 33.1 (11.9) 35.3 (9.2) 24.7 (8.8) 6.1 =.004
Vitality (VT) 33.3 (17.7) 34.3 (15.5) 19.1 (16.5) 4.7 ≤.01
Social functioning (SF) 70.8 (27.9) 67.9 (18.8) 45.6 (24.9) 5.8 =.006
Role—emotional (RE) 48.1 (44.4) 57.9 (40.5) 17.6 (26.7) 5.9 =.005
Mental health (MH) 56.0 (17.8) 63.1 (12.2) 44.0 (18.5) 7.3 =.002
VAS2
Mood (very sad-very happy) 53.3 (16.8) 50.1 (11.2) 43.3 (11.3) 2.4 n.s
Sleepiness (very sleepy-very
alert) 45.2 (16.5) 37.6 (12.4) 27.7 (13.8) 5.4 =.008
SPAQ3
Global seasonalscore (GS score) 12.5 (2.9) 11.8 (2.2) 15.5 (2.9) 10.1 <.001
1The SF-36, high values correspond to feeling better.
2Two bivariate 0–100 visual analogue scales. High values correspond to feeling better.
3GS score from the Seasonal Pattern AssessmentQuestionnaire (SPAQ). High values correspond to more seasonal symptoms.
4.Discussion
Am a i nﬁ n d i n gi nt h i ss t u d yw a st h a tf a t i g u e ,e x c e s s i v e
daytime sleepiness, and health-related quality of life were
improved in persons with seasonal aﬀective disorder (SAD)
and subsyndromal SAD following treatment in a light room.
Results were maintained for at least one month. The results
correspond to and strengthen conclusions drawn in the
previous randomised controlled study, where the level of
depression was reduced after treatment in a light room [18].
There are, to our knowledge, only one previous study
investigated eﬀects on HRQOL following treatment with
BLT in a health care setting and including persons with
SAD [33]. Results from that study are consistent with the
present results and suggest that patients with SAD have a
marked impairment of HRQoL during the winter months
and that treatment results in a corresponding marked
improvementinbothdepressedmoodandHRQOL.Another
study comparing winter versus summer scores indicates that
even though scores for HRQOL in patients with SAD were
markedly low during the winter, they were signiﬁcantly
improved and within the normal range during the summer
[34].
Subjective ratings of mental health (the subscale MCS
in the SF-36) were much lower in the sample at baseline
compared with the Swedish normative data [27]. Results for
the MCS in our study (mean value 32) were well below a
previously proposed cutoﬀ for possible depression (mean
value ≤42) [35]. The degree of impairment corresponds
to results from studies in both seasonal and nonseasonal
depression [33, 34, 36, 37]. The SF-36 VT (vitality) subscale
was remarkably low at baseline in our study (mean value
30.1, SD = 16.8). A corresponding low ﬁgure in a Swedish
general population sample correlates to low ratings of global
health [27]. This is a reminder that there may be substantial
subjective functional impairment not onlyin depression, but
in subsyndromal depression as well. Following treatment
and at the one-month followup, HRQOL scores were
substantially improved and equal to or close to population
norms.
A series of studies performed in other settings than light
rooms from a research group in Finland show that bright
light exposure was eﬀective in improving depressive mood
and HRQOL in healthy subjects with or without seasonal
symptoms [38] and that both exercise and bright light
alone or in combination was eﬀective in relieving depressive
mood and improving HRQOL in healthy employees with
S-SAD [39, 40]. Results from a large cross-sectional study
(N>6600) suggested that in the population, HRQOL
is inﬂuenced by seasonal changes and the illumination
experienced indoors [41]. Preliminary data suggest that
outdoor work during the winter season may have a positive
eﬀect on mood [42].
Excessive daytime sleepiness (EDS) is a symptom com-
monly encountered in clinical practice and may arise from
many somatic and psychiatric disorders. It is also related
to lifestyle behaviors [43]. It is conceptualized as the drive
to fall asleep at inappropriate times and despite attempts8 Depression Research and Treatment
to remain awake, and it is a condition which is relieved by
good sleep [44]. Patient complaints may be expressed in
terms of “tiredness,” “fatigue,” or “lack of energy” rather
than a direct reference to impaired alertness or excessive
sleepiness [43]. Fatigue, on the other hand, has been deﬁned
as an overwhelming sense of tiredness, lack of energy, and
feeling of exhaustion [45]. It is a subjective, unpleasant
symptom which incorporates total body feelings ranging
from tiredness to exhaustion creating an unrelenting overall
condition which interferes with the individuals’ ability to
function to normal capacity [46]. In contrast to EDS, in
the short-term perspective, fatigue is not relieved by sleep.
In sleep medicine, sleepiness and fatigue are considered
two diﬀerent but related concepts with partial overlap that
need separate assessments [47, 48]. Both EDS and fatigue
are common symptoms in major depressive disorders. For
example, prevalence ﬁgures for fatigue in major depressive
disorder range between 73 and 93% [4, 49], but fatigue is
notspeciﬁcfordepression;itcanbemeasured independently
of depression and is prevalent in a large number of other
psychiatric and somatic disorders as well [50]. Excessive
daytime sleepiness (EDS) is commonly viewed as a sign
of disturbed or inadequate sleep and is associated with
diﬀerent types of sleep disorders (such as obstructive sleep
apnea). There is evidence for an association between EDS
and moderate-to-severe depression, [51]. There are several
questionnaires that rate the severity of EDS; one of the most
frequently used is the Epworth Sleepiness Scale (ESS), which
was used in the present study [26, 44]. There are at least ﬁfty
diﬀerent questionnaires that rate the severity of fatigue [52],
the majority of these being disease speciﬁc and not suitable
for the present application.
T oo u rk n o w l e d g e ,t h i si st h eﬁ r s tt i m et h ef a t i g u e
questionnaire (FQ) and the Epworth Sleepiness Scale (ESS)
were used in a controlled clinical study of BLT in SAD and
S-SAD. Fatigue (FQ) was markedly high at baseline (mean
value 19.3) compared with that of the general population
(mean value 12.2) [25]. The increase in daytime sleepiness
( E S S )w a sm o r em o d e r a t ea tb a s e l i n e( m e a nv a l u e1 0 . 0 ) .
Ac u t o ﬀ of ≥10 on the ESS is commonly used to indicate
excessive daytime sleepiness which contrasts to that of
healthy controls (mean value 5.9) but is not indicative of a
high level of daytime sleepiness [26]. The scores on the ESS
improved following BLT, which is consistent with another
clinical study of BLT in SAD in which measures of excessive
daytime sleepiness were used [53].
Common features in the subgroups, independent of the
level of depressed mood, were a high level of fatigue (the
FQ) and low estimates of subjective mental health (the MCS
in the SF-36). These results indicate that there are similarly
low ratings of mental health among persons with SAD and
subsyndromal SAD. Therefore, one may argue that fatigue
rather than depressive mood is the common core symptom
in SAD and S-SAD. In spite of the diﬀerences in baseline
severity of depression and sleepiness, all the three subgroups
beneﬁted from BLT. At the one-month followup, scores for
f a t i g u e( t h eF Q ) ,e x c e s s i v ed a y t i m es l e e p i n e s s( t h eE S S ) ,a n d
health-related qualityoflife (theSF-36)were within (orclose
to) the normal range in all three subgroups (Figure 2). Thus,
even though clustering revealed distinct subgroups at base-
line, there were more similarities between subgroups than
were diﬀerences over time. Therefore, we suggest the term
“winter fatigue” for the combined group of persons with
SAD and S-SAD and for the subgroups a label according to
thesymptoms. Morespeciﬁcally, “simplewinterfatigue”(the
“Mildly depressed-Not sleepy subgroup), “Winter fatigue
with sleepiness”(themildlydepressed-sleepy subgroup),and
“Winter depression” (the depressed-sleepy subgroup) are
suggested as more convenient labels for the clusters. It is not
the ﬁrst time such a suggestionis made; in1986, Muellerand
Davies proposed that seasonal aﬀective disorder should be
classiﬁed as a seasonal energy syndrome [54].
Since cluster analysis always produces clusters, it is
essential to go through a validation procedure to evaluate
whether clusters are useful or meaningful for the clinician.
Group diﬀerences between the clusters on the clustering
variables, on independent variables and over time (group
x time interaction), are three of the most recommended
validation methods [30] and were all used in the present
study. The clusters were validated on cluster variables,
demographic variables, and other independent measures
at baseline. However, there were similar treatment eﬀects
over time. The clusters/subgroups should be regarded as
preliminary until validated in further studies of independent
samples. The majority of subjects in the present study were
considered to have a mild-to-moderate level of depressive
mood, and results can therefore not be generalized to more
severe seasonal depression.
The ESS had an unexpectedly low correlation to all
the other measures in this study. This result contradicts
results from other studies, in which the level of depression
was positively associated with the level of sleepiness [55].
A possible explanation may be that, in this sample, some
persons were later diagnosed as having comorbid sleep
disorders,suchas snoring anddelayedsleepphasesyndrome.
It is well-known that a portion of depressed patients may
have an undiagnosed comorbid sleep-disordered breathing,
mostlyobstructivesleepapnea[51,56,57],andthesamemay
be truefor persons with a seasonal depression. The sample in
the present study was recruited from a random sample of the
general population and not from a patient population. This
procedure made it possible to identify persons with S-SAD
for inclusion in the study. However, even though all subjects
were clinically diagnosed by an experienced psychiatrist, the
risk of missing comorbid disorders may be higher in such a
sample comparedtoasample fromapatientpopulation.The
resultsfrom theclusteranalysis canpossibly beinterpretedin
a similar way since the three empirically derived subgroups
were diﬀerentiated mainly by two variables; depressive mood
(the SIGH-SAD/SR) and excessive daytime sleepiness (the
ESS). In the clinic, this may be a reminder that comorbid
sleep disorders are common and should be considered when
patients report seasonal mood changes.
In conclusion, fatigue, sleepiness, and health-related
quality of life improved in a similar way as measures
of depression in persons with SAD and S-SAD following
treatment with BLT. Exploring treatment eﬀects in empir-
ically derived clusters showed that all the three subgroupsDepression Research and Treatment 9
beneﬁted from bright light therapy and that the eﬀects were
maintained during the one-month followup. A common
feature in the clusters was a high level of fatigue, while levels
of depression and sleepiness diﬀered between groups. The
results support common features in SAD and S-SAD rather
than diﬀerences and point to the usefulness of including a
broader range of outcome measures in future clinical trials.
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